Clinical Trial Detail

NCT ID NCT01116648
Title Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase Ib/II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

peritoneum cancer

Her2-receptor negative breast cancer

fallopian tube cancer

triple-receptor negative breast cancer

ovary epithelial cancer

Therapies

Olaparib

Cediranib + Olaparib

Age Groups: adult senior

No variant requirements are available.